Vertex Kidney Drug Data Sparks 22% Surge in Maze Therapeutics
MAZE sits 24% above its 52-week low of $21.95 on elevated volume (3.5× avg).
Summary
Vertex Pharmaceuticals reported positive Phase 2b results for its APOL1 inhibitor inaxaplin, showing a 42.7% reduction in urine protein in nondiabetic patients with no serious side effects. The data validates the mechanism Maze Therapeutics' MZE829 targets, sending Maze shares up 22% to $27.19. Analysts at H.C. Wainwright and Truist see the results as de-risking Maze's upcoming readout, with Truist noting the market could support two blockbuster drugs. Maze's next trial readout is expected later this year or early 2027, and if MZE829 avoids the mild liver enzyme spikes seen in 13% of Vertex's patients, it could gain a competitive edge.
At the time of this announcement, MAZE was trading at $27.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $21.95 to $53.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.